GB2429152A - Electrochemically activated water for use as a virucide - Google Patents

Electrochemically activated water for use as a virucide Download PDF

Info

Publication number
GB2429152A
GB2429152A GB0517044A GB0517044A GB2429152A GB 2429152 A GB2429152 A GB 2429152A GB 0517044 A GB0517044 A GB 0517044A GB 0517044 A GB0517044 A GB 0517044A GB 2429152 A GB2429152 A GB 2429152A
Authority
GB
United Kingdom
Prior art keywords
solution
virus
activated water
electrochemically activated
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0517044A
Other versions
GB0517044D0 (en
Inventor
Nick Meakin
Robert Kenyon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forum Bioscience Holdings Ltd
Original Assignee
Forum Bioscience Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forum Bioscience Holdings Ltd filed Critical Forum Bioscience Holdings Ltd
Priority to GB0517044A priority Critical patent/GB2429152A/en
Publication of GB0517044D0 publication Critical patent/GB0517044D0/en
Priority to PCT/GB2006/050246 priority patent/WO2007020478A1/en
Publication of GB2429152A publication Critical patent/GB2429152A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/20Elemental chlorine; Inorganic compounds releasing chlorine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/03Electric current
    • A61L2/035Electrolysis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The use of a solution comprising electrochemically activated water to kill or destroy a virus, preferably an avian virus such as avian influenza, infective bronchitis, Gumboro disease, chick anaemia or Marek's disease, is disclosed. The solution preferably comprises both the anolyte and the catholyte solution of electrochemically activated water, and may further comprise an antibiotic agent or drug. The solution may be administered orally, such as in the patient's food or drink.

Description

Virucidal Solutions 1'he present invention relates to improved virucidal
agents, and particularly to virucidal solutions, for killing harmful viruses such as avian viruses. Whilst virucidal agents are known, they are generally harmful substances and contact with them should be avoided. Furthermore, conventional virucidal agents are harmful to the environment and their use should therefore be kept to a minimum. The present invention relates to virucidal agents which are safe and which do not harm the environment. Therefore, the virucidal agents of the invention may be used freely to prevent viral infection and to prevent the spread of viruses.
In particular, the present invention is concerned with killing and reducing the spread of avian viral diseases, such as Avian Influenza (commonly referred to as Third flu"), Infective Bronchitis, Gumboro Disease, Chick Anaemia and Merek's Disease.
Viruses are non-living, infectious or pathogenic agents, containing nucleic acids (i.e., DNA or RNA), which are usually contained in a protein coat. Many different forms of virus exist. They are classified by shape, the nature of their nucleic acids (i.e., whether they have single or double-stranded RNA or DNA), the type of organisms that they infect and the way in which they infect them.
Unlike bacteria or fungi, viruses (essentially, because they are nonliving entities) cannot be controlled by the use of biopesticides or the like. Vaccines may be produced to increase protection against mammalian viral disease.
In the past, common disinfectant materials have been used as virucidal agents. For example, disinfectants containing hypochlorites, such as household bleach, can be effective against viruses. The virucidal activity usually comes from the agents' ability to bond with and destroy the outer surfaces (protein coatings) of viruses.
Influenza is a common virus and there are three types of influenza virus, namely Influenza A, B and C. Influenza A viruses are found in many different animals, 4. 4 including ducks, chickens, pigs, whales, horses, and seals. Influenza B viruses circulate widely only among humans. Influenza A or B viruses cause epidemics of disease almost every winter. In the United States, these winter influenza epidemics can cause illness in lO% to 20% of the total population and are associated with an average of 36,000 deaths and 114,000 hospitahsations per year. Influenza type C infections cause a mild respiratory illness and are not thought to cause epidemics.
Wild birds are the primary natural reservoir for all subtypes of Influenza A viruses and are thought to be the source of Influenza A viruses in all other animals. Most influenza viruses cause asymptomatic or mild infection in birds. However, the range of symptoms in birds varies greatly depending on the strain of virus. Infection with certain avian influenza A viruses (for example, some strains of H5 and H7 viruses) can cause widespread disease and death among some species of wild and especially domestic birds such as chickens and turkeys.
While it is relatively rare for humans to get influenza infections directly from animals, sporadic human infections and outbreaks caused by certain avian Influenza A viruses have occurred. Because avian influenza viruses do not commonly infect humans, there is little or no immune protection against them in the human population. Therefore, when such cross-species infection does occur, the virus tends to spread easily from person to person, causing an influenza pandemic. It is thought that such outbreaks may be triggered by humans living in close proximity to birds, such as chickens, and pigs. This is commonly thought to be how the 1911 influenza pandemic started.
An outbreak of "bird flu" is currently affecting bird populations in countries throughout Asia and a number of human cases also have been reported. Key to containing the outbreak is the culling of sick and exposed birds. For the current outbreak in Asia, governments are culling poultry to try to contain the virus.
Patients are being treated and isolated, and investigations are underway to determine the source of infection. In addition to such culling, and the possible development of a vaccine against this strain of bird flu, the spread of the outbreak could be further contained using the present invention.
Merek's Disease is another example of an avian viral disease. It is caused by a herpes virus and it occurs mainly in chickens under 16 weeks of age. At present there is no known treatment for Merek's Disease and its spread is controlled by vaccination of chicks when they are one day old.
Infective Bronchitis is another avian viral disease and its symptoms include respiratory distress, sneezing and rattling. In laying birds, it is common to observe a drop in egg production, as well as misshaped eggs with low quality. Some strains of the virus may cause severe kidney damage. Once again, at present there is no known treatment for Infective Bronchitis, and its spread is controlled by vaccination.
A further avian viral disease is Chick or Chicken Anaemia. This condition is caused by the Chicken Anaemia Agent (CAA), a primary immune system pathogen which causes multiple anatomic and clinical immunopathologic lesions. Although birds of all ages are susceptible to the virus, embryos and chicks less than 14 days old are prime targets. CAA is extremely hardy and resistant to temperature extremes and most disinfectants, although commercial bleach solutions are reported to kill the virus.
Gumboro Disease (also known as Infectious Bursal Disease (IBD) or Infectious Bursitis) is an avian viral disease caused by a birnavirus. The serotype I virus occurs throughout the world in chickens, whilst the serotype 2 antibody (without disease) is present in turkeys. Different strains of the virus exhibit different virulence. Clinical signs of Gumboro Disease are related to the strain of virus involved. The Gumboro I)isease virus is mainly spread by faeces and litter. People, clothing, vehicles and equipment soiled with contaminated faeces/litter are known to facilitate the spread of the virus. Litter beetles may also be a cause local spread and persistence. Effective cleansing and disinfection is required to remove infection and to reduce the risk of the spread of the virus. Vaccination of susceptible stock also provides protection from the disease.
In light of the foregoing, it is clear that there are a number of avian viral diseases which have serious implications. As many birds, and in particular poultry, are bred for human consumption and this involves keeping large numbers of animals in close proximity to one another and a significant amount of transportation of the animals, it is desirable to be able to disinfect the animals and their housing, transportation vehicles and anyone who comes into contact with them. Prevention of the spread of viruses into the human population is clearly also very important.
The spread of the viruses is currently difficult to control and in some cases the only way to kill the virus is to use strong virucidal agents such as commercial bleach, in combination with treating the subjects with vaccines prior to infection and/or with antibiotics after infection. The strong virucidal agents are generally hazardous liquids and their use near animals such as birds and humans is undesirable. The agents tend to be highly toxic and emit harmful fumes. Therefore, the use of these agents must be kept to a minimum and must be carefully monitored as it poses many risks, including, for example, the contamination of drinking water. Herein, "subjects" are animals including, for example, birds and mammals such as humans.
It is therefore clear that an alternative means for killing viruses and controlling their spread is required. Such means needs to be safe for the subjects it seeks to protect, whilst being effective against the often resilient viruses.
In accordance with a first aspect of the present invention, a solution comprising electrochemically activated water is used to kill or destroy viruses and to control the spread of viral diseases. In one embodiment, the viruses are avian viruses.
Ekctrochemically activated water (EAW), which is also sometimes referred to as "hydroactivated water", is water which has undergone electrochemical activation (ECA). Such treatment involves the exposure of water and the natural salts therein, or salts added to it, to a substantial electrical potential difference.
If one places an anode (+) and a cathode (-) in pure water and applies a direct current, electrolysis of the water will occur at the poles leading to a breakdown of the water into its constituent elements, producing gaseous hydrogen and oxygen.
However, if sodium chloride is added to the water to form a solution, the dominant electrolysis end product is hypochiorite or hypochiorous acid (HOd), a chlorine- based reagent which may be used to kill microorganisms.
The electrochemical activation process is improved by interposing an ionpermeable membrane between the positive and negative electrodes, forming an anode chamber and a cathode chamber. Preferably, the aqueous sodium chloride solution is fed into both the anode chamber and the cathode chamber and the sodium chloride, which is in its ionised form in solution (Na and C1) is exposed to the controlled electrical potential difference between the cathode and the anode. This potential difference causes the Na ions to migrate to the cathode and the C1 ions to migrate to the anode. The membrane which separates the anode chamber and the cathode chamber allows ions to pass unimpeded, whilst the un-ionised water and any organic molecules in the water are unable to pass through the membrane.
The presence of an ion-permeable non-ceramic membrane in the electrolysis apparatus allows the necessary ions to be concentrated in the anode and cathode chambers, which results in the formation of metastable ions with high biocidal activity and very low chlorine levels. Although a similar process takes place in conventional electrochemical activation processes, the presence of anion-permeable membrane prevents the complex reactive species formed at the cathode and anode from reacting with one another and being neutralised. The specific choice of a non- ceramic membrane further refines the chemical processes.
As the electrical potential is applied, high concentrations of Cl- and OHbuild up on the anode side of the membrane and Na and H build up on the cathode side of the membrane. The unstable chemical state results in complex reactions which produce a metastable solution containing a wide variety of very reactive ions and molecules.
It is the formation of these complex chemical species which leads to the formation of solutions described as electrochemically activated water or hydroactivated water.
Some of the reactive constituents formed during the electrochemical activation of the sodium chloride solution include hypochiorite (HC1O), hydrogen peroxide (H202), ozone (O), chlorine (Cl2) and chioric acid (HC1O3). Most of these compounds are formed in the anode chamber. They are acidic, giving the anolyte a pH of between 2.4 and 4 and oxidising activity. In the cathode chamber, the reactive species are basic and are reducing agents. The catholyte will have a pH of between 10 and 12.
The anolyte and catholyte produced by the electrochemical activation of an aqueous sodium chloride solution also exhibit opposing potentials, the anolyte having a redox potential of approximately +lO5OmV, while the catholyte has a redox potential of approximately -850mV. This is compared to the redox potential of the starting material of approximately +300 to 400mV.
In the apparatus with an ion-permeable membrane, two distinct solutions are formed, the catholyte and the anolyte, and these solutions can be separately extracted or they can be mixed.
The anolyte solution exhibits mild oxidative power and can destroy microorganisms, and therefore has useful sterilizing and disinfectant properties. The catholyte has properties which make it useful as a detergent and as a surfactant. Its reducing power also mean that the catholyte is effective in precipitating metal ions out of water and it can be used to soften hard water.
Whilst the oxidative and reductive properties of the anolytes and catholytes of the electrochemically activated water have previously been recognised, it has now unexpectedly been found that the anolyte of electrochemically activated water may be used to kill or destroy viruses, including avian viruses. What is more, the use of such anolyte solutions is safe. Whilst the anolyte solutions are capable of rapidly breaking down the protein coating of a virus, the solutions are benign in terms of fumes, corrosion and their effect on the skin of humans and other animals. The solutions are mildly oxidative.
Therefore, in one embodiment of the present invention, a solution comprising the anolyte of electrochemically activated water is used to destroy or kill viruses and to control the spread of viral diseases. The anolyte contains agents such as hypochiorite and hydrogen peroxide which have virucidal activity.
In another embodiment of the invention, the solution comprises a combination of the anolyte and the catholyte of electrochernically activated water. In a particular embodiment, the catholyte is added to the anolyte in order to adjust the pH of the solution to a desired value. Solutions with a pH of between 6 and 8 may be prepared and used.
What is more, it has been surprisingly found that the ability of the anolyte solutions of the present invention to kill or destroy viruses is not only provided when the solutions have been produced with high residual hypochiorite content of greater than 5Oppm. Rather, it has now been recognised that electrochemically activated water with a much lower chlorine content also exhibits the disinfectant properties, despite containing only little, if any, hypochlorite when generated using nonceramic membranes.
Figure 1 is a graph indicating the ORP (oxidation-reduction potential) of electrochemically activated water in mV versus the electrical current used in its production for an ECA 2000 electrochemically activated water generator (available from Forum Bioscience Holding, Redhill, Surrey, UK).
Figure 2 is a graph indicating the increase in chlorine in ppm with current for an ECA 2000 machine.
Figure 3 is a graph showing the variation of p1-I with current for an ECA 2000 machine.
It is generally believed that the disinfectant activity of electrochemically activated water is a function of the hypochlorite concentration of the water. As the concentration of hypochlorite increases, so does the ORP and the disinfectant activity of the electrochemically activated water. As a result, it is generally considered that the higher the hypochiorite content of the electrochemically activated water, the greater its disinfectant activity. Indeed, it is generally thought that the electrochemically activated water must include at least 50 to 200ppm hypochlorite in order for it to exhibit acceptable disinfectant activity. Where electrochemically activated water has been used in the past as a disinfectant, the hypochlorite concentration has been greater than SOppm and is usually much greater, sometimes as high as 65Oppm.
Therefore, it was previously believed that electrochemically activated water having a chlorine content of less than 8ppm would not exhibit any disinfectant activity and would not be effective against micro-organisms and certainly not effective against resilient viruses.
However, as can be seen from Table 1 below, the ORP of solutions produced on an ECA 2000 machine starts to plateau at 3-4 amps and from 6-8 amps onwards the figure remains almost constant whereas the chlorine content climbs rapidly. If the ORP is a measure of the disinfectant activity then the graphs of Figures 1, 2 and 3 and Table I indicate that electrochemically activated water solutions, produced on an ECA 2000 machine, should be effective disinfectants at total chlorine levels of less than 35ppm.
Table I
Chlorine content Current ORP pH _______ __________ _______ (ppm) 3 1052 2.67 35 4 1086 2.67 58 1104 2.58 95 6 1107 2.39 103 7 1108 2.39 129 8 1111 2.28 134 9 1112 2.23 156 1114 2.19 198 11 1115 2.15 221 12 1115 2.11 226 13 1115 2.11 230 14 1115 2.1 249 1115 2.07 258 16 1115 2.04 295 17 1115 2.02 371 This hypothesis has now been demonstrated. That is, when the electrochemically activated water produced using the above rationale to minimise the chlorine content is diluted with mains water to a chlorine content of less than 8ppm it still exhibits disinfectant activity.
The disinfectant activity of this water is not a result of the hypochiorite in the water, but rather it appears to be due to the presence of an activated chlorine and oxygen species. This activity is thought to be "masked" in conventional clectrochemically activated water by the levels of and the activity of the hypochlorite. It has now been found that the activated chlorine and oxygen species produce a redox potential high enough for the water to have disinfectant activity (greater than +900mV), whilst having a minimal chlorine content.
Tt is thought that the active chlorine and oxygen species in the electrochemically activated water are highly reactive, reacting with many organic compounds including olefins, dienes, sulphides, aromatics, heteroaromatics, terpenes, steroids, fatty acids, flavones, tetracyclines, vitamins, amino acids, proteins, nucleic acids, blood and bile pigments.
The activity of this minimal chlorine electrochemically activated water against bacteria, viruses and fungi species has previously been demonstrated by the inventors. It has been found that electrochemically activated water with a chlorine content of less than 8ppn-i can be used to kill or destroy viruses, including avian viruses.
It is desirable to have electrochemically activated water with a low chlorine content for a number of reasons. Where the water is used with birds, the high chlorine content of conventional electrochemically activated water means that although the - 10 - water is not harmful when it comes into contact with the birds, it should not be ingested. Where the chlorine content of the electrochemically activated water is between 8 and l2Oppm, a bird drinking the water will increase its water intake, as this electrochemically activated water will make it thirsty. This increased water intake leads to wet litter which is undesirable as it is more likely to stick to the birds and cause burning. What is more, the wet litter is more likely to provide a good breeding ground for microorganisms, which promotes the spread of disease. Where the chlorine content exceeds l20ppm, it will kill birds if ingested.
Thus, in another embodiment of the present invention, the solution has a low chlorine content, preferably a chlorine content of less than 8ppm. In some embodiments, the chlorine content may be up to 10, 8, 6, 5 or 4ppm, and may be at least 0.1, 0.2, 0.3, 0.4 or O.5ppm.
The solutions used in the present invention preferably have a redox potential of at least +900mV, and preferably of at least +l000mV or + lO5OmV. Preferably, the solutions used in the present invention include active chlorine and oxygen species and the concentration of the active oxygen is preferably between 11 and 2Omg/1.
In a preferred embodiment, the level of chlorine dioxide (dO2) present in the solutions is less than lOppm, preferably less than 5ppm, and most preferably less than lppm. For example, the level of chlorine dioxide is no more than 9,8, 7,6, 5, 4, 3, 2 or lppm.
In a further preferred embodiment, the level of hypochiorite in the solutions is less than l0ppm, preferably less than 5ppm, most preferably less than lppm. For example, the level of hypochiorite is no more than 9, 8, 7, 6, 5, 4, 3, 2 or lppm.
In another embodiment of the invention, the disinfectant solutions have a pH which is adjusted to a desired value or range. The disinfectant anolyte of the electrochemically activated water has a pH of below 4. 1- lowever, in many applications of the disinfectant solutions, the pH is preferably higher than this. For example, in certain preferred embodiments, the pH of the solution is between 3 and -11 - 8, or between 4 and 7. It is also desirable for the pH to be kept at a constant pH, with variations of 0.5 of a unit or less, and preferably of 0.1 of a unit or less.
Compositions which have a stable pH value of 3-8 or 4-7 are particularly useful in the present invention, as they are advantageous for use in physiological systems, as proposed herein.
The compositions disclosed herein have the advantage that their pH may be adjusted without significant loss of disinfectant and biocidal activity. In one embodiment, the pH of the anolyte solution with a minimal chlorine content is adjusted by adding an amount of the catholyte of the electrochemically activated water sufficient to produce the desire pH value. This combination of the anolyte and the catholyte of electrochemically activated water retains the disinfectant and biocidal activity of the anolyte.
The electrochemically activated water used in the present invention can be produced in a number of ways, including those well known in the art.
Conventional electrolysis processes operate at voltages and/or power densities at which HC1O and/or C102 are produced. Indeed, it is these species in conventional electrochei-nically activated water which is traditionally relied upon for the biocidal activity.
As discussed above, electrochemically activated water with a minimal chlorine content is preferably used in the present invention. The chlorine content of the electrochemically activated water is affected by the amount of sodium chloride in the water prior to the electrochemical activation process, the current used to electrolyse the solution (the size of the current and the length of time the water is exposed to it) and the rate of flow of the salt solution through the different chambers of the electrolytic cell.
Compositions for use in the present invention may be produced by running the electrolysis process at a voltage and/or power density which is higher than that at which 0, and Cl2 are produced, but which is also lower than that at which FIC1O - 12 - and C102 are produced. Preferably, the voltage adjacent to the electrode face is between 1.35 and 1.63V, more preferably between 1.4 and 1.5V and most preferably between 1.42 and 1.47V. It is important to note that these values do not refer to the voltage across the whole system. The chemical reactions are taking place at the face of the electrodes and so it is the voltage here that is significant.
A person skilled in the technical field of the present invention would have no difficulty adjusting the parameters of the electrolysis process in order to achieve the voltage and/or power density at the electrodes required to produce the compositions of the present invention, once he is aware of the required voltage and/or power density at the electrodes relevant to the membrane in use.
The ratio of the anolyte:catholyte flow can be from 5:95 to 95:5 with the optimum flow ratio being be 90:10, whilst the current should be between 1 and 20 amps with the preferred range being 6 to 12 amps.
The variation of the chlorine concentration in ppm with water flow at constant current is shown in Table 2.
Table 2
Total Flow _______ Anolyte _________ Catholyte litres/hr Flow Cl (ppm) ORP pH Flow pH ____________ ________ ___________ ___________ ___________ (l/hr) ___________ 37.2 37.2 0 n/a 6.78 0 n/a 37.2 31.2 200 1053 3.16 6 12.28 39 27.6 250 1060 3.05 11.4 12.19 42 24 250 1069 2.87 18 11.98 42 22.8 300 1072 2.7 19.8 11.82 42 16.2 375 1093 2.45 25.8 11.89 In addition, the application of a low current during the electrochemical activation process also results in a solution with a reduced chlorine content. This is likely to be due to the fact that the lower magnetic field has a lower ability to attract the negatIve chloride ions during the brief period that any specific chloride ion is within - 13 - the electromagnetic field. As a result there is a far greater probability that the electrolysis will involve the water molecules will which will lie alongside the electrodes and produce oxygen based species than chlorine based species.
That the electrochemically activated water produced by the ECA 2000 series machines has an exceptionally high concentration of oxygen is shown in Figure 4.
For comparison, the normal saturated concentration for oxygen in water is approximately 8.3mg/litre. In Figure 4, "Hydroactivc" is the electrochemically activated water anolyte stream from an ECA 2000 machine and "Cell Waste Stream" is the electrochemically activated water catholyte stream from an ECA 2000 machine.
Regardless of the method used to produce the electrochemically activated water, the water has the beneficial properties utilised by the present invention.
Where the chlorine content of the electrochemically activated water is to be limited by using a low sodium chloride concentration in the water fed into the apparatus carrying out the electrochemical activation, the water fed into the apparatus and electrochemically activated preferably has a sodium chloride concentration of between 1000 and 5000ppm, and preferably between 2000 and 3000ppm chloride ion concentration.
The conventional electrochemical activation processes apply a current of approximately 10-20 amps to the sodium chloride solution. In order to reduce the chlorine content of the electrochemically activated water, it is recommended that the current be reduced to between I and 10 amps with the preferred range being between 5 and 9 amps.
The RCA 2000 machine may be preferably used to generate the electrochemically activated water. This system significantly reduces the formation of undesirable trihalomethane and chloroamine by-products.
- 14 - The main principle of the RCA 2000 machines is an electrochemical synthesis of gaseous mixture of oxidants from a dilute solution of sodium chloride under pressure in diaphragm modular electrochemical elements, each of which is a separate electrochemical rector. The block diagram of such a device is presented on Figure 6.
As shown in Figure 6, sodium chloride solution is delivered into the electrochemical reactor. The process results in a partial division of sodium chloride solution into activated chlorine and oxygen based oxidants in the anode chamber, and hydrogen and sodium hydroxide formed in the cathode chamber. The oxidants produced in the anode chamber together with micro-droplets of water are collected (preferably in a darkened acid resistant air tight chemical drum). The electrochemically activated water is then delivered by the injection pump into the part of water to be processed resulting in a dilute solution of oxidants in the final treated water. Hydrogen is generated in the cathode chambers of electrochemical elements and is vented to air through the catholyte discharge tube.
Previous equipment used a ceramic membrane to separate the solutions resulting from close contact with the electrodes. The applicant of the present application has developed the "flat" core which consists of two half cells working at +15 to 0 volts and 0 to -15V, working back to back where the water to be processed flows across the electrodes and the electrode pairs (and thus the solutions) are separated by an ion exchange membrane. It is this core which can preferably be used to produce the electrochemically activated water which is described herein. It is nonceramic.
The apparatus preferably has a feedback mechanism to maintain a constant current, which is dependent upon the ionic strength of the water, which is in turn dependent upon the salt content and the nature of the water used.
Provided that the storage conditions are suitable, the electrochemically activated water produced accordmg to the present invention can be storedfor periods of weeks or months. In a preferred embodiment, the electrochemically activated water can be stored for more than 72 hours.
- 15 - As discussed above, the disinfectant activity of the minimal chlorine electrochemically activated water is due to active chlorine and oxygen species in the water. It is clear that if gas is allowed to escape from the water during its storage or use, the activity will be diminished or lost. Therefore, it is necessary to ensure that the water is stored in a closed system which will keep the loss of gas from the water to a minimum. Any stirring or other agitation of the water should also be avoided, as this will encourage gas to escape from the water.
When stored in sealed bottles with minimal head space, the dissolved active oxygen species will remain in solution above the saturated oxygen in water concentration of approx 8.3mgs/iitre for a considerable period of time, thus maintaining the activity of the product (see Figures 4 and 5).
Figure 5 is a graph showing a three-day study of dissolved oxygen concentrations vs. time for electrochemically activated water produced by an ECA 2000 machine.
The electrochemically activated water solutions of the present invention are ecologically friendly and present no problems for the environment.
This is shown by the concentrations of chlorite (Gb2), chlorate (C103) and perchlorate (do4) measured in neat freshly prepared solution, recorded in Table 3.
Table 3 - Concentrations of chlorine species found in neat ciectrochemically activated water as produced in ECA 2000 machine Species Concentration Chloride Ci 2600-2800 mg/kg Hypochborite Cl0 9 mg/i Chiorite Cl02 <0.2 mg/i Chlorate C103 0.3-1.2 mg/l Perchiorate Ci04 8-13 mug/I In one embodiment of the present invention, the solutions comprising electrochemically activated water are used as one might use a conventional - 16- disinfectant. The solutions may be sprayed on any surface which might be contaminated. Thus, the walls, floor and ceiling of the birds' housing may be sprayed, as well as other surfaces, such as feeding troughs and the like. A fine mist of the solution is sufficient for the virucidal effect. Also, vehicles used to transport the birds may also be sprayed, as well as any other buildings, vehicles, etc. with which the birds, feathers, excrement and the like could come into contact. The solutions may be used liberally, due to their non-hazardous nature. This is also of benefit to the people working with the birds or in the vicinity of the birds. The electrochemically activated water is not harmful if it comes into contact with their clothes or skin and it does not produce harmful or unpleasant fumes. The solutions may even be used to wash the workers' clothes, shoes or even hands, without causing harm.
Where they are used to clean surfaces as described above, the solutions according to the present invention may have a relatively high chlorine content, that is greater than about 8ppm and the electrochemically activated water may be produced using known or conventional processes and apparatus. Alternatively, the solutions may have a relatively low chlorine content, that is no higher than about 8ppm, produced using the methods and apparatus discussed above.
In a further embodiment of the invention, solutions with a iow chlorine content may be used in further useful ways. The birds themselves could be sprayed with these solutions. As they contain little or no hypochiorite or hydrogen peroxide, these solutions do not cause harm if they come into contact with the birds and so such direct application is safe. In another embodiment of the invention, the birds' food is treated with the lowchlorine solutions; for example, it may be sprayed with the solutions before being fed to the birds. This would result in the low-chlorine solutions being ingested by the birds. Finally, in yet another embodiment, an effective dose of the solutions may be added to the birds' normal drinking water.
At effective concentrations, the low-chlorine solutions may be safely ingested with the birds' food or as drinking water without causing harm to the birds.
- 17 - In yet another embodiment of the present invention, the electrochernically activated water is used in conjunction with an antibiotic agent or drug. As indicated in the experimental results discussed below, the electrochemically activated water does not interfere with the activity of antibiotic drugs such as lincospectin and so it is envisaged that the water may be used in conjunction with such antibiotics. This could involve simultaneous, sequential or separate administration of the electrochemically activated water and an antibiotic agent or drug. In one embodiment, the antibiotic may be added to the solution comprising electrochemically activated water. The amount of antibiotic used in conjunction with the electrochemically activated water may represent the conventional dose of said antibiotic. Alternatively, the dose may be less than the dose required when the antibiotic is administered on its own, that is, without the electrochemically activated water of the present invention.
According to a second aspect of the present invention, methods of killing or destroying viruses are provided, the methods comprising exposing viruses to the solutions comprising electrochemically activated water, including solutions according to the first aspect of the invention and as described herein.
According to a third aspect of the present invention, solutions comprising electrochemically activated water, including solutions according to the first aspect of the invention and as described herein, are provided for use in the treatment or prevention of viral infections. Preferably, the solutions are to be administered to a subject prior to, during or after exposure to a virus. 1'he subjects are animals such as birds and mammals, including humans.
According to a fourth aspect of the present invention, there is provided the use of solutions comprising electrochemically activated water, including solutions according to the first aspect of the invention and as described herein, in the manufacture of a medicament for treating or preventing viral infection.
- 18 - Details of the studies conducted into the efficacy of the solutions comprising electrochemically activated water against viruses and its interaction with known antibiotics are set out below.
Experiments - Influenza A Virus Experimental Procedure The study was performed to evaluate the virucidal efficacy of electrochemically activated water against Influenza A virus. Influenza A virus subtype (ATCC-VR- 1520) was chosen as a cell culture adapted prototype strain representative of Avian Influenza A virus subtype HINI for virucidal efficacy testing purposes.
The electrochemically activated water (also referred to in the discussion of this study as the test substance) was generated using an ECA 2000 machine (available from Forum Bioscience Holding, Redhill, Surrey, UK). The machine was set 9 amps ( 0.1 amp) and was fed with an aqueous salt solution comprising 2400 to 3000ppm NaC1.
The study was conducted using standard test procedures for determination of the efficacy of antimicrobial agents against viruses in suspension (American Standard Test Method, ASTM E 1052-96). The test procedure incorporated three elements; evaluation of cytotoxicity of the test substance for the host ccli line, evaluation of test substance interference in the assay system, and quantitative suspension tests in the presence and absence of organic soil. Influenza A virus was assayed in cell culture and quantified by calculation of 5O% Tissue Culture Infectious Dose (TCID5()). Virucidal efficacy of the test substance was assessed by calculation of log1() reduction in cytopathic effect by subtraction of TCID5() values obtained from treated samples and positive (untreated) controls.
Influenza A virus VR-1520 (sourced from LGC Promochem, Queens Road, Teddington, Middlesex, TWI I OLY, England) was received in the form of a iyophiiised preparation. Influenza A virus cell culture fluid lysate was prepared by passage of ATCC-VR-1520 twice in Madin Darby Canine Kidney (MDCK) cells at 33 C 2 C. Ccli culture medium (virus growth medium) was harvested when - 19 - cytopathic effect (CPE) was maximal (approximately 48 hours post infection), aliquoted and stored at -75 C.
The electrochemically activated water was produced on the day of analysis using a machine as described above. Following priming of the machine for several minutes to achieve illumination of the green work' LED display. The electrochemically activated water was produced for approximately 30 minutes and run to waste before collection of approximately I OOmls of the water into a sterile container.
Five lots of the electrochemicaily activated water were prepared for use in this study. Each lot was used on the same day as manufacture. Prior to testing, the test substance was stored at room temperature.
Analysis of free chlorine content of the test substance was carried out using the Palintest . Free chlorine with diethyl-p-phenylene diamine (DPD) in buffered solution to produce a pink colouration. The intensity of the colour is proportional to the free chlorine concentration and was measured using a comparator disc (CD/Ui 1/05). Three dilutions of test substance were prepared using distilled water, namely 1/10, 1/50 and 1/100.
1 Omls of each dilution was added to a clean square test tube and one DPD tablet added. The tablet was broken up to dissolve using a plastic probe. The cell was placed into a comparator and the colour of the solution matched with the disc. Free chlorine concentration (mg/i), corresponding to the colour match was recorded for each dilution.
Cytotoxicity of the test substance for the detector cell line (MDCK cells) , was assessed in triplicate samples. An initial 1/5 dilution of the test substance was prepared in cell culture dilution medium made up as follows. To SOOmls of Modified Eagle Medium (MEM, Sigma M-5650), SOmls of Foetal Bovine Serum (FBS, Sigma F-2442), Smls of antibiotic/antimycotic solution (bOX, Sigma A- 5955), Smls of L-Glutamine (200mM, Sigma G-7513) and Smls of non- essential - 20 - amino acids (NEAA, Sigma M-7145) were added using aseptic procedures and swirled to mix.
Further two fold dilutions of the test substance were prepared in cell culture medium from 1/10 to 1/160. i00t1 of each dilution was inoculated into 10 replicate wells of 96-well cell culture plate containing a confluent monolayer of MDCK cells.
1 O0.tl of cell culture dilution medium was inoculated into appropriate wells (up to 8 wells/plate) as negative controls. Plates were placed in a moist container and incubated at 33 C 2 C. Plates were examined microscopically for signs of cytotoxicity after 48 hours incubation.
The potential for disinfectant to interfere with the ability of the virus to infect the detector cell line used to assay the virus was assessed. Medium from 3 x 96-well cell culture plates containing confluent monolayers of MDCK cells was discarded. Cell monolayers were then washed by addition of lOO.tl of PBS to each well and discarded. 1/10 and 1/00 (v/v) dilutions of the electrochemically activated water were prepared in virus growth medium and 1OO.tl of each dilution was added to (3 x 12) replicate wells (per dilution) of a 96-well cell culture plate containing confluent monolayers of MDCK cells. i00t1 of untreated virus growth medium was added to 3 x 12 replicate wells as untreated controls.
Cells treated with the electrochemically activated water and untreated control cells were challenged with Influenza A virus suspension (106 dilutions). lOOpJ of each virus dilution was added to 10 replicate wells containing untreated and treated (with the electrochemically activated water) virus growth medium. Plates were placed in a moist container and incubated at 33 2 C for 7 days. Following incubation, cells were examined microscopically for signs of virus induced CPE. Individual wells were scored as positive or negative for virus CPE.
A quantitative suspension test for the assessment of virucidal efficacy of the electrochemically activated water against Influenza A virus was set up in 2 phases.
In the first phase, a range of dilutions of electrochernically activated water was tested for virucidal efficacy in the absence of organic load. In the second phase of - 21 - the study dilutions showing virucidal efficacy in phase 1 were tested for efficacy in the presence and absence of organic load (no added protein, 0. 3% Foetal Bovine Serum and I % Foetal Bovine Serum). Test samples and controls (excluding virus) were prepared as shown in Tables 4 and 5.
Table 4 - Quantitative suspension test: Preparation of samples and controls (Study Phase 1) Sample Diluent Virus Disinfectant Final Sample time type (iii) suspension (jtl) dilution points _________ _______ (tl) ____________ __________ (mm) Negative 5000 - - N/A 0 control Test I - 500 4500 Neat 1, 5, 10 & 30 Test 2 - 500 4500 1/10 1, 5, 10 & 30 Test 3 - 500 4500 1/100 1,5, 10 & 30 Test 4 - 500 4500 1/250 1, 5, 10 & 30 Positive 4500 500 - N/A 0, 1, 5, 10 & 30 control Table 5 - Quantitative suspension test: Preparation of samples and controls (Study Phase 2) Sample Diluent Virus Test Bovine Sample time type (il) suspension substance serum points ___________ _________ (j.tl) (jil) (il) (mm) Negative 5000 - - - 0 controls Positive 4550 450 - N/A 0, 1, 5, 10 & 30 controls Test 1 50 450 4500 - 1, 5, 10 & 30 Replicate 2 Test 1 50 450 4500 - 1, 5, 10 & 30 Replicate 2 Test 1 50 450 4500 - 1, 5, 10 & 30 Replicate_3 __________ ______________ Test 2 - 450 4500 50 1, 5, 10 & 30 Replicate_I ___________ Test 2 - 450 4500 50 1, 5, 10 & 30 Replicate 2 _________ Test 2 - 450 4500 50 1, 5, 10 & 30 Replicate 3 Test 3 - 450 4500 50 1, 5, 10 & 30 Replicate I ___________ ______________ _____________ I - 22 - Test 3 - 450 4500 50 1, 5, 10 & 30 Replicate 2 Test 3 - 450 4500 50 1, 5, 10 & 30 Replicate 3 Test 4 50 450 4500 2 - 1, 5, 10 & 30 Replicate_1 __________ Test 4 50 450 4500 2 - 1, 5, 10 & 30 Replicate_2 __________ Test 4 50 450 4500 2 - 1, 5, 10 & 30 Replicate_3 __________ ______________ ____________ Test 5 - 450 4500 2 50 1, 5, 10 & 30 Replicate I ___________ Test 5 - 450 4500 2 50 1, 5, 10 & 30 Replicate 2 __________ ______________ Test 5 - 450 4500 2 50 1, 5, 10 & 30 Replicate 3 __________ ______________ Test 6 - 450 4500 2 50 1, 5, 10 & 30 Replicate_1 __________ Test 6 - 450 4500 2 50 1, 5, 10 & 30 Replicate_2 __________ ______________ Test 6 - 450 4500 2 50 1, 5, 10 & 30 Replicate_3 __________ _____________ Foetal Bovine serum (30% solution) 2 Test substance diluted in 1/9 in de-ionised water to produce a final dilution of 1/10 in the test samples Virus suspension was added to appropriate samples and vortex mixed. 200t1 aliquots of test sample and positive and negative controls were taken at specified timed intervals following vortex mixing and immediately diluted in I 800j.il of virus growth medium (10 dilution). Further tenfold dilutions of test samples and positive controls were prepared from 102 to 108 in virus growth medium (102 and 10 dilutions of negative control samples were prepared in virus growth medium).
Medium from 96-well cell culture plates containing confluent monolayers of MDCK cells was discarded and cell monolayers washed with PBS (100tl/well). 100tl of virus growth medium was added to each well.
Dilutions of test samples, positive and negative controls were added to appropriate wells of a 96-well cell culture plate containing confluent monolayers of MDCK cells (10 replicate wells per dilution). i00t1 of virus growth medium was added to wells designated for cell controls. Plates were placed in a moist container and incubated at - 23 - 33 C. After 7 days incubation, plates were examined for virus induced CPE and individual wells scored positive or negative for CPE.
Virus inactivation as a result of the action of the disinfectant was quantified by subtraction of the virus titres obtained from test samples and the positive controls.
Standard errors and 95% confidence interval were calculated for each titration. The virus titre was calculated as follows. For virus titration, a tenfold dilution series was prepared and each dilution inoculated into 8 replicate wells containing detector cells. At the end of the culture period, each well is scored as positive or negative and each set of dilution is evaluated for the proportion of positive and negative cultures. The titre is expressed at 50% Tissue Culture Infectious Dose (TCID5).
The TCID5J is a standard measure of virus titre and is defined as the virus dose capable of infecting one half of the inoculated cultures. The TCID5() value is calculated using the method of Karber: -log1() TCID5() = log1> starting dilution- (Sp-0.5) log1() dilution factor.
Thus for the data presented in Table 7 below, if 8 replicate wells were inoculated with 100d volumes; -log10 TCID50 = 4 - (1.75 - 0.5).1 = -4 1.25 = -5.25 i.e. TCID5() occurs at a dilution of i05 25 Table 6 - Example end point dilution assay data Dilution CPE Proportion (P)1 P(1-p) 10-4 8/8 1.0 0 10-5 5/8 0.625 0.234 10-6 1/8 0.125 0.109 10-7 0/8 0 0 ________________ _________________ _________________ Sum ()0.343 P = proportion of wells showing positive for cytopathic effect.
The standard error in this type of assay depends on the number of replicate wells used per dilution of the sample i.e. the more replicates used, the more accurate the determination of virus titre.
The standard error of the estimate of virus titre (S TCID)5, is calculated as follows: - 24 - S log10 TCID5() = Li] p(1-p)/n-1 Where = the constant interval between log dilutions p = the proportion of infected wells n = the number of wells tested Thus for the data in Table 7: S log1Q TCID5() = iV 0.343/7 = 0.221 and the standard error at 95% probability level is calculated as: 1.96 x 0.221 = 0.434 logs Therefore, the titre of the sample from the data shown in Table 4 (per lOO.tl) can be expressed at 5.25 0.434 logs, giving a minimum titre of 4.82 and a maximum titre of 5.68.
To express virus titre per ml, values are adjusted to 6.25 0.434 logs, giving a minimum titre of 5.82 and a maximum titre of 6.68.
Results and Discussion Results of available chlorine analysis on the test substance using the Palintest are
shown in Table 7.
1'able 7 - Available chlorine results (Palintest) Test substance Date / Available Chlorine (mg/L) dilution __________ __________ _______________ 14.05.2003 15.05.2003 09.09.2003 10.09.2003 17.09.2003 1/10 v/v 3.0 3.0 3.5 3.5 3.0 1/50 v/v 0.5 1.0 1.5 1.5 >1.0, <1.5 1/100 v/v <0.5 >0.5, <1.0 1.0 1.0 >0.5, <1.0 Variation in the available chlorine levels in the electrochemically activated water was noted between days and between dilutions. Levels of available chlorine (mg/L) varied from 3O-35mg/L for the 1/10 dilution from 25 to 75mg/L for the 1/50 dilution and from <50-100 mg/L for the 1/100 dilution. The Palintest is a broad - 25 - indicator of available chorine and had previously been noted that variations in result were obtained from different dilutions. The subjective nature of the Palintest may contribute to the slight observed variation in levels of available chlorine level between test substance generated on different days.
Results of the electrochenncally activated water cytotoxicity for the host cell line are
shown in Table 8.
Table 8 - Cytotoxicity Test Sample Cytotoxicity (-log10 dilution of test substance) Replicate 1 <1/5 Replicate 2 <1/5 Replicate 3 <1/5 Electrochemically activated water was not cytotoxic for the host cell line over the dilution range tested (1/5 to 1/160). Cytotoxicity was therefore not a factor in quantification of virucidal activity of the test substance.
Results of the effect of electrochemically activated water on the ability of the virus to infect the host cells are shown in Table 9.
Table 9 - Virus interference test Sample Proportion of wells positive for cytopathic effect Cells treatment InF'A (V/03/18) 10 InF'A (V/03/18) 106 ____________________ Rep' I Rep' 2 Rep 3 Rep' I Rep' 2 Rep 3 Control (untreated) 10/10 10/10 10/10 10/10 10/10 10/10 Test substance (10') 10/10 10/10 10/10 10/10 10/10 10/10 Test substance (102) 10/10 10/10 10/10 10/10 10/10 10/10 I-lost cells (MDCK) treated with low dilutions (10-' and 102) of test substance were able to support the growth of test virus at high dilution (10 and 106). The test substance did not compromise the ability of the host cell line to support the growth of virus was therefore not a factor in quantification of virucidal activity.
- 26 - Virucidal efficacy of electrochemically activated water was quantified by suspension test. Phase I of this study assessed a range of dilutions of electrochemically activated water (undiluted, 1/10, 1/100 and 1/250) for virucidal activity against Influenza A virus in the absence of organic load (see Tables 10 and 11).
Table 10 - Virucidal efficacy against Influenza A virus: Virus recovery Sample Virus recovery (-log10 TCID50) / Contact time 0 1 mm 5 mins 10 mins 30 mins Negative control 0.5 NT NT NT NT Positive control 6.4 6.1 6.0 6.2 6.3 Hydroactive undiluted NT S 0.5 0.5 0.5 0.5 ECA water 1/10 v/v NT 2.4 1.8 1.3 0.5 RCA water 1/100 v/v NT 5.8 5.0 4.9 4.6 ECA water 1/250 v/v NT 6.3 6.1 5.8 5.9 Table 11 - Virucidal efficacy against Influenza A virus: Reduction in virus infectivity Sample Reduction in Infectivity (-log10 TCID50) / __________________________ ___________ Contact time ___________ 1 mm 5 mins 10 mins 30 mins Test substance neat = 5.6 5.5 2 5.7 2 5.8 Test substance 1/10 v/v 3.7 4.2 4.9 2 5.8 Test substance 1/100 v/v 0.3 1. 0 1.3 1.7 Test substance 1/250 v/v 0 (-0.2) 0 (-0.1) 0.4 0.4 The electrochemically activated water (undiluted and diluted 1/10) showed significant virucidal activity achieving >Slog1() reduction in virus infectivity after contact times of 1 minute and 30 minutes respectively. Based on these results, electrochemically activated water undiluted and diluted 1/10 (v/v) were selected for testing in Phase 2 of the study in the absence and presence of organic load.
Electrochemically activated water diluted 1 / 1 00 showed marginal virucidal activity (1.7 log10 reduction in virus infectivity after a contact time of 30 minutes).
Electrochemically activated water diluted 1/250 (v/v) showed insignificant virucidal (<O.5log1() after 30 minutes).
Phase 2 of this study assessed electrochemically activated water (undiluted and 1/10) in the absence and presence of organic load (0.3% FBS and 1% FBS). The - 27 - electrochemically activated water (undiluted) showed efficient virucidal activity reducing virus titre by greater than 5 log1() after all contact times tested (1, 5, 10 and minutes) in the absence and presence of organic load (see Tables 13 and 14).
Table 12 - Electrochemically activated water (undiluted): Virucidal efficiency against Influenza A virus: Virus recovery Sample Description Virus recovery_(-log10_TCID50) / Contact time 0 1 mm 5 mins 10 mins 30 mins Negative control 1 0.5 NT NT NT NT Negative control 2 0.5 NT NT NT NT Negative control 3 0.5 NT NT NT NT Mean titre of negative 0.5 - - - Positive control 1 5.8 5.6 5.8 6.1 5.7 Positive control 2 5.6 5.9 5.8 5.9 5.5 Positive control 3 6.1 6.1 5.9 5.7 5.6 Mean titre of positive 5.83 5. 87 5.83 5.9 5.6 ECA water (no protein) 1 NT 0.5 0.5 0.5 0.5 ECA water (no protein) 2 NT 0.5 0.5 0.5 0.5 ECA water (no protein) 3 NT 0.5 0.5 0.5 0.5 Mean titre of test samples NT 0.5 0.5 0.5 0.5 ECA water (0.3% FBS) I NT 0. 5 0.5 0.5 0.5 ECA water (0.3% FBS) 2 NT 0.5 0.5 0.5 0.5 ECA water (0.3% FBS) 3 NT 0.5 0.5 0.5 0.5 Mean titre of test samples NT 0.5 0.5 0.5 0.5 ECA water (1% FBS) I NT 0.5 0.5 0.5 0.5 ECA water (1% FBS) 2 NT 0.5 0.5 0. 5 0.5 ECA water (1% FBS) 3 NT 0.5 0.5 0.5 0.5 Mean titre of test samples NT 0.5 0.5 0.5 0.5 Table 13 - Electrochemically activated water (ECA) (undiluted): Virucidal efficiency against Influenza A virus: Reduction in virus infectivity Sample Reduction in Infectivity (-log10_TCID50)1/Contact time I mm 5 mins 10 mins 30 mins ECA water, undiluted (no protein) ? 5.37 ? 5.33 ? 5.4 ? 5.1 ECA water, undiluted (0. 3% FBS) ? 5.37 ? 5.33 ? 5.4 ? 5.1 ECA water, undiluted (1% FBS) ? 5.37 = 5.33 ? 5.4 ? 5.1 Mean of triplicate samples
S S
- 28 - The electrochemically activated water (diluted 1/100) showed virucidal efficacy dependent on time and the absence and presence of organic load. Greater than 5log10 reduction in virus titre was achieved after contact times of 5 minutes in the absence of organic load. The presence of organic load delayed virucidal effect with >Slog1 reduction in virus infectivity achieved after contact times of 10 and 30 minutes in the presence of 0.3% FBS and 1% FBS respectively (see Tables 15 and 16).
Table 14 - Electrochemically activated water (1/10 v/v): Virucidal efficiency against Influenza A virus: Virus recovery Sample Description Virus recovery_(-log10_TCID50) / Contact time ______________________ 0 1 mm 5 mins 10 mins 30 mins Negative control 1 0. 5 NT NT NT NT Negative control 2 0.5 NT NT NT NT Negative control 3 0.5 NT NT NT NT Mean titre of negative 0.5 - - - - Positive control 1 6.3 6.0 6.4 6.0 6.2 Positive control 2 6.4 6.0 6.0 6.3 6.0 Positive control 3 6.3 5.9 6.2 6.4 6.3 Mean titre of positive 6.33 6. 2 6.23 6.17 ECA water (no protein) 1 NT 1.2 0.5 0.5 0.5 ECA water (no protein) 2 NT 0.7 0.5 S 0.5 0.5 ECA water (no protein) 3 NT 1.9 0.7 0.5 0. 5 Mean titre of test samples NT 1.27 S 0.57 0.5 0.5 ECA water (0.3% FBS) I NT 3.6 2.3 1.3 0.5 ECA water (0.3% FBS) 2 N1' 2.7 1.6 0.6 0.5 RCA water (0.3% FBS) 3 NT 3.2 2.3 1.5 0.5 Mean titre of test samples NT 3.17 2.07 1. 13 0.5 ECA water (1% FBS) 1 NT 3.3 2.4 1.4 0.5 ECA water (1% FBS) 2 NT 3. 4 2.4 1.5 0.5 ECA water (1% FBS) 3 NT 4.1 3.3 2.9 1.5 Mean titre of test samples NT 3.6 2.7 1.93 0.83 Table 15 Electrochemically activated water (ECA) (1:10 v/v): Virucidal efficiency against Influenza A virus: Reduction in virus infectivity Sample Reduction in Infectivity (-log10 TCID50)1/Contact time I mm 5 tnins 10 mins 30
S S
- 29 - ECA water, undiluted (no protein) 4.7 5.63 2 5.73 2 5.67 ECA water, undiluted (0.3% FBS) 2.8 4.13 5.1 2 5.67 ECA water, undiluted (1% FBS) 2. 37 3.5 4.3 2 5.34 Mean of triplicate samples Statistical data gathered from the above discussed studies are set out in Tables 16, 17 and 18.
Table 16 - Electrochemically activated water (ECA): Virucidal efficacy against Influenza A virus: Virus recovery (Study Phase 1) Sample description Virus recovery (-log10 TCID50) I Contact time _____________________ 0 1 mm 5 mins 10 mins 30 mins Positive control 6.4 6.1 6.0 6.2 6.3 Standard error 0.167 0.163 0.167 0.153 0.183 95% confidence interval 0.327 0.32 0.327 0.3 0.359 ECA water Neat NT 0.5 0.5 0.5 0.5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water 1/10 NT 2.4 1.8 1.3 0.5 Standard error 0.167 0.153 0.183 0 95% confidence interval 0.327 0.3 0.359 0 ECA water 1/100 NT 5.8 5.0 4.9 4.6 Standard error 0.191 0.167 0.163 0.224 95% confidence interval 0.374 0.327 0.319 0.439 ECA water 1/250 NT 6.3 6. 1 5.8 5.9 Standard error 0.211 0.194 0.153 0.183 95% confidence interval 0.414 0.38 0.3 0.359 Table 17 Electrochemically activated water (undiluted): Virucidal efficacy against Influenza A virus: Virus recovery (Study Phase 2) Sample description Virus recovery (- log10 TCID50) I Contact time 0 1 mm 5 mins 10 mins 30 mins Positive control 1 5.8 5.6 5.8 6.1 5.7 Standard error 0.153 0.1 0.153 0.163 0.141 95% confidence interval 0.3 0.196 0.3 0.319 0.276 Positive control 2 5.6 5.9 5.8 5.9 5.5 Standard error 0.1 0.163 0.167 0.163 0 95% confidence interval 0.196 0.319 0.327 0.319 0 - 30 - Positive control 3 6.1 6.1 5.9 5.7 5.6 Standard error 0.163 0.163 0.183 0. 133 0.1 95% confidence interval 0.319 0.319 0.359 0.261 0.196 ECA water (no protein) I NT 0.5 0.5 0.5 0.5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water (no protein) 2 NT f 0.5 0.5 0.5 0.5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water (no protein) 3 NT 0.5 0.5 0.5 0. 5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water (0.3%FBS) I NT 0.5 S 0.5 0.5 S 0.5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water (0.3% FBS) 2 NT 0.5 0.5 S 0.5 0. 5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water (0.3% FBS) 3 NT 0.5 0.5 0.5 S 0. 5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water (1% FBS) I NT 0.5 0.5 0.5 0.5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water (1% FBS) 2 NT 0.5 0.5 0.5 0.5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 ECA water (1% FBS) 3 NT 0.5 0.5 0.5 0.5 Standard error 0 0 0 0 95% confidence interval 0 0 0 0 Table 18 - Electrochemically activated water (1/10 dilution): Virucidal efficacy against Influenza A virus: Virus recovery (Study Phase 2) Sample description Virus recovery (-log10 TCID50) I Contact time 0 1 mm 5 mins 10 mins 30 mins Positive control 1 6.3 6.0 6.4 6.0 6.2 Standard error 0.183 0.203 0.203 0.167 0.191 95% confidence interval 0.359 0.398 0.398 0.327 0.374 Positive control 2 6.4 6.0 6.0 6.3 6.0
___ I ____
- 31 - Standard error 0.167 0.167 0.167 0.133 0.167 95% confidence interval 0.327 0.327 0.327 0.261 0.327 Positive control 3 6.3 5.9 6.2 6.4 6.3 Standard error 0.183 0.163 0.153 0.167 0.211 95% confidence interval 0.359 0.319 0.3 0.327 0.414 ECA water (no protein) I NT 1.2 0.5 0.5 0.5 Standard error 0.213 0 0 0 95% confidence interval 0.427 0 0 0 ECA water (no protein) 2 NT 0.7 0.5 0. 5 0.5 Standard error 0.133 0 0 0 95% confidence interval 0.261 0 0 0 ECA water (no protein) 3 NT 1.9 0.7 0. 5 0.5 Standard error 0.163 0.133 0 0 95% confidence interval 0.32 00314 0 0 ECA water (0.3% FBS) 1 NT 3.6 2.3 1.3 0.5 Standard error 0.167 0.183 0.183 0 95% confidence interval 0.327 0.359 0.359 0 ECA water (0.3% FBS) 2 NT 2.7 1.6 0.6 0.5 Standard error 0.133 0.1 0.1 0 95% confidence interval 0.261 0.196 0.196 0 ECA water (0.3% FBS) 3 NT 3.2 2.3 1.5 0.5 Standard error 0.153 0.183 0.141 0 95% confidence interval 0.3 0.359 0.276 0 ECA water (1% FBS) 1 NT 3.3 2.4 1.4 0.5 Standard error 0.133 0.1 0.1 0 95% confidence interval 0.261 0.196 0.196 0 ECA water (1% FBS) 2 Ni' 3.4 2.4 1.5 0.5 Standard error 0.203 0.1 0 0 95% confidence interval 0.398 0.196 0 0 ECA water (1% FBS) 3 NT 4.1 3.3 2. 9 1.5 Standard error 0.163 0.133 0.163 1.141 95% confidence interval 0.319 0.261 0.319 0.276
Conclusions
The tested electrochemically activated water was not cytotoxic to the host cell line at dilution tested. Furthermore, it did not interfere with the ability of the host cell line to support the growth of the test virus.
S
- 32 - Electrochemically activated water (undiluted) showed efficient virucidal activity reducing virus titre by greater than Slog1() after all contact times tested (1, 5, 10 and minutes) in the absence and presence of organic load.
Electrochemically activated water (diluted I / 10) showed virucidal efficacy dependant on time and the absence and presence of organic load. Greater than Slog1() reduction in virus titre was achieved after contact times of 5 minutes in the absence of organic load. The presence of organic load delayed virucidal effect, with >Slog1) reduction in virus infectivity achieved after contact times of 10 minutes and 30 minutes in the presence of O.3% PBS and 1% PBS respectively.
Experiments - Infections Bronchitis Virus Experimental Procedure This study was performed to evaluate the virucidal efficacy of the electrochemically activated water against Infectious Bronchitis Virus (IBV). The Infectious Bronchitis Virus used in the study was the Beaudette strain ATCC-VR-22. The host cell line used was Vero cells (African green monkey kidney cells), ECACC number 84113001.
The test procedure incorporated three elements, namely the evaluation of the cytotoxicity of the electrochemically activated water (also referred to herein as the test substance) for the host cell line, evaluation of the test substance interference with the assay system, and a quantitative suspension test for the determination of virucidal activity of the test substance against IBV.
The IBV was assayed in cell culture (Veto cells) and quantified by calculation of 50% Tissue Culture Infectious Dose (TCID50). Virucidal efficacy of the test substance was assessed by calculation of log1() reduction in TC1D511 of the virus following treatment with the test substance and quantified by subtraction of TCID5() values obtained from treated samples and positive (untreated) controls.
The IBV (sources from LGC Promochem, Queens Road, Teddington, Middlesex, TWI 1 OLY, England) was received as a lyophilised preparation. The virus was - 33 - adapted to cell culture by repeated passage (7 passages) in Vero cells. After each passage, virus suspension (cell culture medium) was harvested when cytopathic effect was maximal (approximately 72 hours post infection) and stored at -.75 C.
Virus suspension harvested from the 7th passage in Veto cells was concentrated by polyethylene glycol precipitation. The precipitate was centrifuged and the pellet resuspended in phosphate buffered saline and stored at -75 C.
The electrochemically activated water was produced on the day of analysis using a machine as described above. Following priming of the machine for several minutes to achieve illumination of the green work' LED display, the electrochemically activated water was produced for approximately 10 minutes and run to waste before collection of approximately 200m1 of the water into a sterile container. The water was used on the same day as manufacture. Prior to testing, the water was stored at room temperature.
Analysis of free chlorine content of the test substance was carried out using the Palintest at two dilutions, namely 1/10 and 1/50. The free chlorine concentration (mg/i) was measured, as discussed above.
Cytotoxicity of the test substance for the host cell line (Vero cells) was tested. An initial 1/5 dilution of the test substance was prepared in cell culture dilution medium made up as follows. To 500m1 of 1)ulbecco's Modified Eagle Medium (DMEM, Sigma M-5671), lOmi of Foetal Bovine Serum (FBS, Sigma F-7524), 5m1 of antibiotic/antirnycotic solution (bOX, Sigma A-5955) and 5m1 of L- Glutamine (200mM, Sigma G-7513) were added using aseptic procedures and swirled to mix.
Further four-fold dilutions of the test substance were prepared in dilution medium.
100t1 of each dilution was inoculated into 10 replicate wells of 96-well cell culture plate containing a confluent monolayer of Vero cells. I OOpJ of dilution medium was inoculated into appropriate wells (up to 8 wells/plate) as negative controls. Plates were placed in a moist container and incubated at 37 2 C.
- 34 - Cell rnonolayers were examined microscopically for signs of cytotoxicity after 7 days incubation. Cell viability was tested using Methyithiatetrazolium (MTT) assay. MTT solution was added to monolayers and incubated at 37 2 C for 2 hours. The coloured product (formazan) was eluted using Dimethylsuiphoxide (DMSO) and absorbance read at 540nm. Dilution showing 50% end point of cyto toxic effect was calculated by nonlinear regression using binary data.
The potential for the test substance to interfere with the ability of the host cell line to support the growth of the virus was tested in an interference test. Medium from two 96-well cell culture plates containing confluent monolayers of Vero cells was discarded. Cell monolayers were then washed by addition of iOOj.d of PBS to each well and discarded. Dilutions of the test substance were prepared in dilution medium and i00. ti of each dilution was added to 11 replicate wells (per dilution) of a 96-well cell culture plate containing confluent monolayers of Vero cells. In a second (control) plate, IOOp.l of dilution medium was added to each well.
Cells treated with the test substance and untreated control cells were challenged with IBV suspension. l00.tl of each virus dilution was added to 10 replicate wells containing treated cells and untreated control cells. The plates were placed in a moist container and incubated at 37 2 C for 7 days. Following incubation, cells were examined microscopically for signs of virus induced cytopathic effect (CPE).
Individual wells were scored as positive or negative for virus CPE.
A quantitative suspension test was used to determine virucidal efficacy of the test substance against IBV. Test samples and controls were prepared as shown in Table 19.
Table 19 - Quantitative suspension test: Preparation of samples and controls Sample Diluent Virus Test Final Sample time type (j.tl) suspension Substance dilution' points _________ ________ (il) (il) __________ (mm) Negative 2000 - - N/A 0 control Test 1 - 500 2000 Undiluted 1, 5, 10 & 30 Test 2 - 500 2000 i Undiluted 1, 5, 10 & 30 - 35 Test 3 - 500 2000 1/10 1, 5, 10 & 30 Test 4 - 500 2000 1/10 1, 5, 10 & 30 Positive 2000 500 - N/A 1, 5, 10 & 30 control I Positive 2000 500 - N/A 1, 5, 10 & 30 control 2 Dilutions of the product were prepared to produce a final dilution as specified, accounting for the volume of the virus suspensions in the test procedure.
Virus suspension was added to appropriate samples and vortex mixed. 5OOtl aliquots of test sample and positive and negative controls were taken at specified timed intervals following vortex mixing and immediately diluted in I 500jd of dilution medium, producing an initial 1/5 dilution. Further four-fold dilutions of test samples and positive controls were prepared from 1/2 to 1/327680 in dilution medium. For the negative controls, 1/20 and 1/80 dilutions were prepared in dilution medium. Dilutions of test samples, positive and negative controls were added to appropriate wells of a 96-well cell culture plate containing confluent monolayers of Vero cells (10 replicate wells per dilution). lOOjil of dilution medium was added to wells designated for cell controls. The plates were placed in a moist container and incubated at 37 2 C. After 7 days incubation, plates were examined for virus induced CPE and individual wells scored positive or negative for CPE.
TCID5( values were calculated using the method of Karber. Virus inactivation as a result of the action of the disinfectant was quantified by subtraction of the virus titres obtained from test samples and the positive controls. Standard errors and 95% confidence interval were calculated for each titration. These calculations are all explained above.
Results and Discussion Results of available chlorine analysis on the test substance using the Palintest are
shown in Table 20.
Table 20 - Available chlorine results (Palintest) Test substance Available Chlorine (mg/i) dilution (v/v) Diluted (comparator reading) Corrected for dilution - 36 - L 1/10 3.0 30 I 1/50 1.5 75 Levels of available chlorine varied from 30mg/i for the 1/10 dilution to 75mg/l for the 1/50 dilution.
Results of the electrochemically activated water cytotoxicity for the host cell line are shown in Figure 7 and in Table 21 below.
Table 21 - Cytotoxicity Test Sample Cytotoxicity (50% end point, CE5O)' 95% CI' Test substance 1:1.66 1:1.04 - 1:2.64 Data taken from Figure 7, 50% end point of cytotoxic effect Although the undiluted test substance showed cytotoxicity fro the host cell line, no cytotoxicity was observed when the solution was diluted from 1/5 to 1/20480. In quantitative suspension tests, the lowest dilution of the test substance inoculated onto host cells for virus recovery studies was 1/20 (demonstrated as noncytotoxic).
Cytotoxicity of the test substance for the host cell line was therefore not a factor in quantification of virucidal activity of the test substance.
The results of the interference test conducted to show the potential of the test substance to affect the ability of the host cell line to support the growth of the virus are shown in Table 22.
Table 22 - Virus interference test TCID50/ml Untreated cells Treated cells 5.42 5.42 No difference was observed in virus recovered from cells treated with dilutions of the test substance (from 1/20 to 1/327680) in comparison to the untreated controls. TCID5) values were the same from the two titrations, indicating that the - 37 - test substance did not compromise the ability of the host cell line to support the growth of virus.
Virucidal activity of the test substance, diluted (1/10, final dilution) and undiluted, against IBV using a quantitative suspension test is shown in Tables 23 and 24 below.
Table 23 - Virucidal efficiency of test substance against IBV: Virus recovery Sample Description I Virus recovery (-log10 TCID50) / Contact time _______________________ 1 mm 5 mm 10 mm 30 mm Positive control 1 5.06 4. 94 4.88 5.00 Positive control 2 4.88 4.94 4.88 5.00 Positive control (mean) 4.97 4.94 4.88 5.00 Test substance (neat) I 2.0 2.0 2.0 2.0 Test substance (neat) 2 2.0 2.0 2.0 2.0 Test substance (neat, mean) 2.0 2.0 2. 0 2.0 Test substance (1/10) 1 2.3 2.24 2.12 2.0 Test substance (1/10) 2 2. 3 2.36 2.12 2.0 Test substance (1/10, mean) 2.3 2.3 2.12 2.0 Table 24 Virucidal efficiency against IBV: Reduction in virus titre (Log10 CCID50), mean of triplicate samples Sample Virus recovered (Log10 CCID50), mean of triplicate samples/Contact time _____________________ I mm 5 mm 10 mm 30 mm Test substance (neat) ? 2.97 ? 2.94 = 2.88 = 3.00 Test substance (1/10) ? 2.67 ? 2.64 ? 2.76 ? 3.00 Undiluted test substance showed efficient virucidal activity against IBV with no virus recovered after all contact times tested (1, 5, 10 and 30 minutes). Log1(, reduction in virus titre of =2.97 log10 was achieved after a contact time of 1 minute and ?3 log10 after a contact time of 30 minutes, equivalent to ?99.9% virus inactivation.
- 38 - Test substance diluted 1/10 was less efficient with some virus recovery from the lower dilutions. However, after a contact time of 30 minutes, 23 log10 reduction in virus titre was observed, equivalent to ?99.9% virus inactivation.
When tested undiluted, virus inactivation was demonstrated to assay baseline levels (no virus recovered). The relatively low titre of the IBV challenge virus may have prevented demonstration of greater log reduction in virus titre.
Conclusions
The tested electrochemically activated water was not cytotoxic to the host cell line at the dilutions used for virus recovery studies (2 1/20). Furthermore, it did not interfere with the ability of the host cell line to support the growth of the test virus.
Electrochemically activated water (undiluted) showed efficient virucidal activity reducing virus titre by greater than 2.88- 3.0 log1(1 after all contact times tested (1, 5, and 30 minutes).
Experiments - Effect of Electrochemically Active Water on Amoxycillin Experimental Procedure This study was carried out to determine the effect of electrochemically activated water on the minimum inhibitory concentrations (MIC) and the minimum microbiocidal concentrations (MMC) of amoxycillin, when tested against the bacterial organism Salmonella abonji (also referred to herein as the test organism).
The experiments were carried out using Salmonella (enteritidis) abony NCTC 6017 (from the National Collection of Type Cultures, London, England). The bacterial inoculum was prepared from a fresh working culture grown on Tryptone Soya Agar (TSA - Oxoid CMI3I) prepared by suspending 4Og of TSA in I litre of distilled water and sterihsing by autoclaving at 121 C for 15 minutes.
The culture was incubated at 37 2 C for approximately 24 hours. Immediately before the test, surface growth was harvested and directly suspended into sterile O.1% Peptone saline (prepared by dissolving 1. Og/htre bacteriological peptone (Oxoid L37) and 8.9g/litre sodium chloride in I litre of distilled water and - 39 - sterilising by autoclaving at 121 C for 15 minutes) and standardised to give 35-4O% light transmission at 520 nm on aJenway 6105 Spectrophotometer - an appropriate yield of i0 colony family units (cfu) per ml. The suspension was diluted further using Mueller Hinton Broth (MHB) to give approximately iO cfu/ml. The MHB was prepared by suspending 2Ig of MHB (Oxoid CM405) in I litre of distilled water and sterilising it by autoclaving at 121 C for 15 minutes. The final suspension was then used immediately as the inoculum.
The electrochemically activated water was generated immediately before use and was diluted with sterile distilled water to give 3ppm free chlorine. The chlorine content was measured using a Palintest kit. The amoxycillin was formulated in sterile distilled water at 100 mg/mi. It was also formulated in the electrochemically activated water (3ppm chlorine) at 100 mg/mi. Sixteen halving dilutions of each formulation were prepared, using sterile distilled water and electrochemically activated water (3ppm chlorine) respectively. Dilutions were prepared in glass containers and were stored protected from light.
The MIC test was conducted approximately 1 hour, 6 hours and 24 hours after formulation of the amoxycillin, in order to determine whether its activity was affected in a time-dependent manner by the electrochemicaily activated water.
For each formulation of amoxycillin, the test organism was added to a single row of wells on a microtitre plate to give a final viable inoculum concentration of approximately i0 cfu/ml. The amoxycillin was then added. The final test concentrations were prepared by transferring 20.tl of the amoxycillin dilutions to the appropriate wells on the test plate, each well containing 1 80tl of inoculated MHB. These additions represented a 10-fold dilution of the amoxycilhn. The final concentrations of the amoxycillin in the wells were, therefore, 10000, 5000, 2500, 1250, 625, 312.5, 156.25, 78.13, 39.06, 19.53, 9.77, 4.88, 2.44, 1.22, 0. 61, 0.31 and 0.15 ig/ml. The highest three concentrations were insoluble in MHB.
Negative control wells to demonstrate growth of the test organism in the absence of amoxycillin were established. Sterility controls for both media and amoxycilhin were also established. The electrochemically activated water (3ppm chlorine) was also - 40 - added to wells containing the test organism, in order to assess its effect on the growth of the organism.
The lid and base of each test plate were sealed together using masking tape and the plates secured to an automatic plate shaker and shaken for 2 mInutes. The masking tape was then removed and the plates incubated at 37 2 C for approximately 24 hours.
All wells showing no growth of the test organism and also some wells showing growth were subcultured using a sterile i ti inoculating ioop onto TSA and incubated at 37 2 C for approximately 24 hours.
After incubation, the wells of each microtitre plate were examined for the presence of microbial growth (turbidity) and the end point (MIC) for the amoxycillin recorded as the lowest concentration that completely inhibited growth of the test organism. The lowest concentration of the amoxycillin showing no growth on sub- culture onto agar media was recorded as the MMC.
Results & Conclusion
The results of the tests to determine the MIC and MMC values of amoxycillin in the absence and presence of electrochemically activated water (3ppm chlorine) against Salmonella aboty 1, 6 and 24 hours after formulation are shown in Table 25.
Table 25 - MIC and MMC values of amoxycillin tested against Salmonella abony Solvent MIC ig/m1 MMC ig/ml 1 hour 6 hours 24 hours 1 hour 6 hours 24 hours Sterile distilled water 0. 61 0.61 0.61 0.61 0.61 0.61 Electrochemically 1.22 1.22 1.22 1.22 1.22 1. 22 activated water Amoxycillin demonstrated good antimicrobial activity towards Salmonella abony, both in the absence and presence of electrochen- ucally activated water. The MMC values - 41 - were found to be the same as the MIC values, demonstrating that arnoxycillin showed bactericidal rather than bacteriostatic activity.
The wells treated with the electrochemically activated water showed that it did not affect the growth of the test organism. The growth control wells demonstrated adequate growth of the test organism, whereas the sterility control wells demonstrated that both the amoxycillin and the growth medium were sterile.
Although the MIC value doubled when amoxycillin was formulated in electrochemically activated water compared with water, it was considered that this increase probably fell within the range of variation expected for a test system of this nature and may not have been due to the deactivation of amoxycillin by the electrochemically activated water.
It was concluded that the electrochemically activated water did not substantially affect the activity of amoxycillin, when challenged with Salmonella aboty.
Experiments - Efficacy of Electrochemically Active Water and Lincospectin Experimental Procedure This study was carried out to determine the minimum inhibitory concentrations (MIC) and the minimum microbiocidal concentrations (MMC) of lincospectin and electrochemically activated water, when tested against three bacterial organisms, namely Bscherichia co/i, Salmonella abonj and Campy/obacterje;uni. The effect of the electrochemically activated water on the activity of lincospectin was also determined by pre-incubating the lincospectin in the presence of electrochemically activated water before testing the two substances together.
The expcriments were carried out using Salmonella enteritidis,.) abony NCTC 6017 and Campylobacterjejuni NCTC 11351, both from the National Collection of Type Cultures, London, England, and Escherichza co/i NCIMB 8545 from the National Collection of Industrial and Marine Bacteria, Aberdeen, Scotland.
- 42 - The bacterial inocula were prepared from fresh working cultures grown on Mueller 1-Jinton Agar (MHA) for Escherzchza co/i and Salmonella abony, and on Campylobacter Agar contaming 5% lysed horse blood (CA) for (Jampylobacterjejuni. The MHA was prepared by suspending 38g of MHA (Oxoid CM337) in 1 litre of distilled water, bringing the suspension to the boil to dissolve completely and then sterilising by autoclaving at 121 C for 15 minutes. The CA was prepared by suspending I4.8g of Campylobacter Agar in 380ml of distilled water, bringing the suspension to the boil to dissolve completely and then sterilising by autoclaving at 121 C for 15 minutes.
This was then cooled at 50 C or below and 20m1 of Lysed Horse Blood (Oxoid - SR48) aseptically added.
All cultures were incubated at 37 2 C for approximately 24 hours. Campylobacter jejuni was grown under microaerophilic conditions (Oxoid Campylobacter Gas Generating Kit - CampyGen CNO35A and an Oxoid Anaerobe Jar). Surface growth was harvested and directly suspended into sterile O. l% Peptone saline (discussed above) and standardised to give 30-40% light transmission at 520nm on a Jenway 6105 Spectrophotometer - an approximate yield of 108 cfu/ml. These suspensions were further diluted using Mueller Hinton Broth (MHB) as discussed above, to give approximately i05 cfu/ml. These final suspensions were then used immediately as inocula.
A preliminary test was conducted in order to determine MIC values for both lincospectin and electrochemically activated water, prior to a main test with the two test substances added together.
Lincospectin was formulated in sterile distilled water to give a concentration of 8 mg/mi. Dilutions from this concentration were prepared on a 96-well microtitre plate in serial 1:1 v/v steps by transferring i00. .t1 test substance solution into the adjacent well on the microtitre plate containing l00tl sterile distilled water. This gave a range of test substance concentrations from 8mg/ml to 3.9tg/ml, that were equivalent to ten times the final test concentrations.
- 43 - The electrochernically activated water was generated immediately before use and was diluted with sterile distilled water to give 3ppm free chlorine. The chlorine content was measured using a Palintest kit and was found to be 35-4Omg/ml using a 1/10 dilution and l5Omg/ml using a 1/100 dilution.
The electrochemically activated water was then diluted on a separate dilution plate using sterile distilled water to give a range of halving concentrations from lOO% v/v to 0.05% v/v.
The final test concentrations were prepared by transferring 20tl of each test substance dilution from the corresponding wells on the dilution plates to the appropriate wells on separate test plates. Each well already contained 160tl of MHB, to which 20d of the test organism inoculum, prepared in MHB, had been added. One test organism was used per row on the plate at a final viable inoculum concentration of approximately i04 cfu/ml. These additions represented a 10-fold dilution of the test substance concentrations such that the final test concentrations were in the range of 800-0.39jtg/ml for lincospectin and 10-0.005% for the electrochemically activated water.
20il of each test organism were inoculated into single wells containing only 1 60tl MHB, plus 20ti sterile distilled water, to act as positive growth controls. Wells containing 200j.tl MHB only were incubated as media sterility controls. Wells containing I 80il MHB plus 20il of the test substance dilutions only were incubated as test substance sterility controls.
The lid and base of each test plate were sealed together using masking tape and the plates secured to an automatic plate shaker and shaken for 2 minutes. The plates were then incubated at 37 2 C for approximately 24 hours.
Following visual assessment of the test plates for MIC concentrations, all wells showing no growth of test organisms were subcultured using a sterile 1tl inoculating loop onto MHA (discussed above). Wells showing growth of the test organism were also included as a control to determine the time required to see r 4 - 44 - visible growth. The plates were incubated as described above for growth of test organisms in order to determine MMC concentrations.
The main test was conducted using all three test organisms. Dilutions of lincospectin and electrochemically activated water in sterile water were prepared as previously described. In order to evaluate whether the electrochemically activated water affected the MIC of lincospectin, lincospectin was formulated at 8mg/ml in electrochemically activated water at concentrations of IOO%, lO%, l% and O.l% v/v. These solutions were left for one hour at room temperature in order to allow time for any reaction between the lincospectin and the electrochemically activated water. After this time, the formulations of lincospectin were diluted with the same concentrations of electrochemically activated water that they had been dissolved in.
This was performed on a dilution plate as previously described.
Test plates were prepared as previously described. A separate test plate was prepared for each test organism. Rows therefore contained: lincospectin dissolved and diluted with electrochemically activated water at 100%, lO%, l% and O.l% v/v; lincospectin dissolved and diluted with sterile distilled water; a growth control; and a media sterility control. Two separate plates were established in order to act as sterility controls for all test substance dilutions.
The plates were sealed, shaken and incubated as previously described, except the plate containing Campy/obacterjejuni and its sterility control plate were incubated under microaerophilic conditions for approximately 72 hours at 37 2 C.
MIC and MMC concentrations were assessed as previously described. For Campy/obacterjejunz the wells were subcultured onto CA plus 5% lysed horse blood plates and incubated under microaerophilic conditions for approximately 48 hours at 37 2 C.
Results & Conclusion
Results of the tests to determine the MIC and MMC values are shown in Table 26.
- 45 - Table 26 - MIC and MMC values from preliminary test Test organism MIC ig/m1 MMC tg/m1 Fischeric/jia co/i 50 >800 Salmonella abony 50 >800 It was not possible to determine the MMC using the range of concentrations tested as light growth was seen on plates subcultured from wells treated with 50 to 800j.ig/mI. This indicated that lincospectin was bacteriostatic rather than bacteriocjdal at these concentrations.
The electrochemically activated water did not inhibit growth at any of theconcentrations tested, despite the fact that it was expected, by its nature, to exhibit antimicrobial activity. One possible explanation is that the electrochemically activated water was deactivated by the organic load present in the broth. Therefore, this type of study may not be suitable for determining the antimicrobial activity for substances of this nature.
The results of the main test are shown in Tables 27 and 28 below.
Table 27 - MIC values (tg/ml) for lincospectin treated with a range of concentrations of electrochemically activated water Test organism % electrochemically activated water _____________________ 0 0.1 1 10 100 Escherzchia co/i 50 25 50 25 50 Salmonella abony 50 50 50 50 50 Camp yloba cterjejunz 25 25 25 50 50 Table 28 - MMC values (tg/m1) for lincospectin treated with a range of concentrations of electrochemically activated water Test organism % electrochemically activated water _____________________ 0 0.1 1 10 100 Escbcrzchia co/i >800 >800 >800 >800 >800 Salmonella abony >800 >800 >800 >800 >800 Campylobacterjejuni 50 50 50 50 50 - 46 It can be seen that the electrochemically activated water did not affect the activity.
It was not possible to determine MMC values for Escherzchza co/i and Sa/mone/la abony as light growth was seen on plates from all wells treated with the MIC and above.
Therefore, a bacteriostatic rather than a bacteriocidal effect was seen at these concentrations. However, for Campylobacterjejunz the MMC values suggest a bacteriocidal effect.
It was concluded that the electrochemically activated water did not substantially affect the activity of lincospectin, when challenged with the three bacterial to organisms tested. It was not possible to determine the MIC or MMC of the electrochemically activated water in this study.
The results of the discussed experiments show that the electrochemically activated water is capable of killing various viruses and these results can be interpreted as indicating that the water will also be effective in killing other types of avian virus, such as those mentioned specifically herein.

Claims (36)

  1. - 47 - Claims 1. Use of a solution comprising electrochemically activated
    water to kill or destroy a virus, preferably an avian virus.
  2. 2. A use as claimed in claim 1, wherein the solution comprises the anolyte solution of electrochemically activated water.
  3. 3. A use as claimed in claim 2, wherein the solution further comprises the catholyte solution of electrochemically activated water.
  4. 4. A use as claimed in any one of the preceding claims, wherein virus is an avian virus.
  5. 5. A use as claimed in claim 4, wherein the virus is a virus causing Avian Influenza, Infective Bronchitis, Gumboro Disease, Chick Anaemia or Merek's Disease.
  6. 6. A use as claimed in any one of the preceding claims, wherein the solution has a redox potential of at least +900mV.
  7. 7. A use as claimed in any one of the preceding claims, wherein the solution has a chlorine content of less than 8ppm.
  8. 8. A use as claimed in any one of the preceding claims, wherein the solution includes an active oxygen species in an amount between 13 and 20mg/i.
  9. 9. A use as claimed in any one of the preceding claims, wherein the solution further comprises an antibiotic agent or drug.
  10. 10. A use as claimed in claim 9, wherein the antibiotic drug is lincospectin.
    - 48 -
  11. 11. A method of killing or destroying a virus comprising exposing the virus to a solution comprising electrochemically activated water.
  12. 12. A method as claimed in claim 11, wherein the solution comprises the anolyte solution of electrochemically activated water.
  13. 13. A method as claimed in claim 12, wherein the solution further comprises the catholyte solution of electrochemically activated water.
  14. 14. A method as claimed in any one of claims 11 to 13, wherein the virus is an avian virus, such as a virus causing Avian Influenza, Infective Bronchitis, Gumboro Disease, Chick Anaemia or Merek's Disease.
  15. 15. A method as claimed in any one of claims 11 to 14, wherein the solution has a redox potential of at least +900mV.
  16. 16. A method as claimed in any one of claims 11 to 15, wherein the solution has a chlorine content of less than 8ppm.
  17. 17. A method as claimed in any one of claims 11 to 16, wherein the solution includes an active oxygen species in an amount between 13 and 20mg/i.
  18. 18. A method as claimed in any one of claims 11 to 17, wherein the method further comprises exposing the virus to an antibiotic agent or drug.
  19. 19. A method as claimed in claim 18, wherein the solution comprising the electrochemically activated water further comprises an antibiotic agent or drug.
  20. 20. A method as claimed in claim 18 or 19, wherein the antibiotic drug is lincospectin.
    - 49 -
  21. 21. A solution comprising electrochemically activated water, for use in the treatment or prevention of a viral infection, wherein the solution is administered to a subject prior to, during or after exposure to the virus.
  22. 22. A solution as claimed in claim 21, wherein the solution has a redox potential of at least +900mV.
  23. 23. A solution as claimed in any one of claims 21 or 22, wherein the solution has a chlorine content of less than 8ppm.
  24. 24. A solution as claimed in any one of claims 21 to 23, wherein the solution includes an active oxygen species in an amount between 13 and 20mg/i.
    25. A solution as claimed in any one of claims 21 to 24, wherein the solution is administered as part of the subject's food or drink.
  25. 25. A solution as claimed in any one of claims 21 to 25, for use in conjunction with an antibiotic agent or drug.
  26. 26. A solution as claimed in claim 25, wherein the solution further comprises the antibiotic agent or drug.
  27. 27. A solution as claimed in claim 25 or 26, wherein the antibiotic drug is lincospectin.
  28. 28. Use of a solution comprising electrochemically activated water, in the manufacture of a medicament for the treatment or prevention of infection of a subject by a virus, wherein a therapeutically effective dose of the electrochemically activated water is administered to the subject.
  29. 29. A use as claimed in claim 28, wherein the solution has a redox potential of at least +900mV. 4 7
    - 50 -
  30. 30. A use as claimed in any one of claims 28 or 29, wherein the solution has a chlorine content of less than 8ppm.
  31. 31. A use as claimed in any one of claims 28 to 30, wherein the solution includes an active oxygen species in an amount between 13 and 20mg/i.
  32. 32. A use as claimed in any one of claims 28 to 31, wherein the solution is administered orally.
  33. 33. A use as claimed in any one of claims 28 to 32, wherein the solution is to be administered in conjunction with an antibiotic agent or drug.
  34. 34. A use as claimed in claim 33, wherein the solution and the antibiotic agent or drug are administered simultaneously, sequentially or separately.
  35. 35. A use as claimed in any one of claims 33 or 34, wherein the solution comprising the electrochemically activated water further comprises an antibiotic agent or drug.
  36. 36. A use as claimed in any one of claims 33 to 35, wherein the antibiotic drug is lincospectin.
GB0517044A 2005-08-19 2005-08-19 Electrochemically activated water for use as a virucide Withdrawn GB2429152A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0517044A GB2429152A (en) 2005-08-19 2005-08-19 Electrochemically activated water for use as a virucide
PCT/GB2006/050246 WO2007020478A1 (en) 2005-08-19 2006-08-18 Virucidal solutions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0517044A GB2429152A (en) 2005-08-19 2005-08-19 Electrochemically activated water for use as a virucide

Publications (2)

Publication Number Publication Date
GB0517044D0 GB0517044D0 (en) 2005-09-28
GB2429152A true GB2429152A (en) 2007-02-21

Family

ID=35097975

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0517044A Withdrawn GB2429152A (en) 2005-08-19 2005-08-19 Electrochemically activated water for use as a virucide

Country Status (2)

Country Link
GB (1) GB2429152A (en)
WO (1) WO2007020478A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2442519A (en) * 2006-10-02 2008-04-09 Forum Bioscience Holdings Ltd Wound treatment compositions
WO2010080572A1 (en) * 2008-12-18 2010-07-15 Cunningham Emmett M Treatment or prevention of viral infection by chlorination
CN103924005A (en) * 2013-01-16 2014-07-16 辽宁成大生物股份有限公司 Detection method for influenza virus inactivation test verification
WO2021191226A1 (en) * 2020-03-23 2021-09-30 Sanixtreme Gmbh & Co. Kg Mouthwash, in particular for treating the human oral and pharyngeal cavity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002271A1 (en) * 1994-07-15 1996-02-01 Medical Discoveries, Inc. Electrically hydrolyzed salines as in vivo microbicides for the treatment of cardiomyopathy and multiple sclerosis
WO2005065383A2 (en) * 2003-12-30 2005-07-21 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution, processes for producing same and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049750A1 (en) * 2001-12-10 2003-06-19 Radical Waters (Ip) (Pty) Limited Method for treating infectious conditions of mucosae and muco-cutaneous tissue
GB0407478D0 (en) * 2004-04-01 2004-05-05 Forum Bioscience Holdings Ltd Disinfectant solutions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002271A1 (en) * 1994-07-15 1996-02-01 Medical Discoveries, Inc. Electrically hydrolyzed salines as in vivo microbicides for the treatment of cardiomyopathy and multiple sclerosis
WO2005065383A2 (en) * 2003-12-30 2005-07-21 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution, processes for producing same and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Antimicrob Chemother; Vol 46, pp 363-368 (2000). Tagawa et al. "Inactivation of a hepadnavirus by electrolysed acid water" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2442519A (en) * 2006-10-02 2008-04-09 Forum Bioscience Holdings Ltd Wound treatment compositions
WO2010080572A1 (en) * 2008-12-18 2010-07-15 Cunningham Emmett M Treatment or prevention of viral infection by chlorination
CN103924005A (en) * 2013-01-16 2014-07-16 辽宁成大生物股份有限公司 Detection method for influenza virus inactivation test verification
WO2021191226A1 (en) * 2020-03-23 2021-09-30 Sanixtreme Gmbh & Co. Kg Mouthwash, in particular for treating the human oral and pharyngeal cavity

Also Published As

Publication number Publication date
GB0517044D0 (en) 2005-09-28
WO2007020478A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
Jorquera et al. Disinfection of seawater for hatchery aquaculture systems using electrolytic water treatment
EP1740226A1 (en) Disinfectant solutions
JP6708715B2 (en) Antimicrobial agent containing hypochlorous acid
Acosta et al. High-level biocidal products effectively eradicate pathogenic γ-proteobacteria biofilms from aquaculture facilities
CN101247724A (en) Oxidation method and compositions therefor
KR20100031468A (en) Anti-bacterium deodorant
CN106456655A (en) Antimicrobial sanitizer compositions and their use
CN102228058B (en) Citric acid composite disinfectant
ZA200502838B (en) Biocide composition and related methods
GB2429152A (en) Electrochemically activated water for use as a virucide
EP0190797A2 (en) Method for killing viruses and composition therefor
CN111647567A (en) Acid-resistant salmonella bacteriophage and composition, kit and application thereof
JP7397668B2 (en) Antimicrobial agents containing hypochlorous acid
CN109699686A (en) A kind of disinfectant for killing avian influenza virus
KR20200009520A (en) Process for Compositions of Disinfectants for High Pathogenic Avian Influenza Virus Including nano- and ionic-Minerals
KR20190070457A (en) Composition for preventing Chicken Colibacillosis comprising chlorine dioxide as supplement for drinking water
KR20180133576A (en) Anti-freezing disinfectant composite and method for preventing disease and spread using the same
WO2022126976A1 (en) Special disinfectant for meat, and preparation method therefor
WO2017089947A2 (en) Composition comprising bacteriophages for reducing, eliminating and/or preventing salmonella enteritidis, salmonella typhimurium and salmonella paratyphi b
US20240099301A1 (en) Disinfecting and Sanitizing Composition, Method for Preparing the Composition and Use of Same
Balavenkatasubbaiah et al. Serichlor, a new disinfectant in Indian sericulture
WO2023142221A1 (en) Disinfection product based on citric acid and natural naphthoquinone compound
CN104351911A (en) Food freshness-retaining, sterilization and disinfection method
Punyadarsaniya et al. Understanding the Bactericidal and Virucidal Capacity of Potassium Peroxymonosulfate in Varied Environments and Its Utilization in Eradicating Germs on Diverse Surfaces and Clothing
Reddy et al. Evaluation of disinfectants against Newcastle disease virus in the presence of organic matter and water hardness

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)